AU2017331930B2 - Crystalline forms - Google Patents

Crystalline forms Download PDF

Info

Publication number
AU2017331930B2
AU2017331930B2 AU2017331930A AU2017331930A AU2017331930B2 AU 2017331930 B2 AU2017331930 B2 AU 2017331930B2 AU 2017331930 A AU2017331930 A AU 2017331930A AU 2017331930 A AU2017331930 A AU 2017331930A AU 2017331930 B2 AU2017331930 B2 AU 2017331930B2
Authority
AU
Australia
Prior art keywords
crystalline form
vol
piperazine
amino
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2017331930A
Other languages
English (en)
Other versions
AU2017331930A1 (en
Inventor
Daniel Leuenberger
Stefan Reber
Markus Von Raumer
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Viatris Asia Pacific Pte Ltd
Original Assignee
Viatris Asia Pacific Pte Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Viatris Asia Pacific Pte Ltd filed Critical Viatris Asia Pacific Pte Ltd
Publication of AU2017331930A1 publication Critical patent/AU2017331930A1/en
Application granted granted Critical
Publication of AU2017331930B2 publication Critical patent/AU2017331930B2/en
Assigned to VIATRIS ASIA PACIFIC PTE. LTD. reassignment VIATRIS ASIA PACIFIC PTE. LTD. Request for Assignment Assignors: IDORSIA PHARMACEUTICALS LTD
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6558—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
    • C07F9/65583—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system each of the hetero rings containing nitrogen as ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
AU2017331930A 2016-09-22 2017-09-21 Crystalline forms Active AU2017331930B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP2016072562 2016-09-22
EPPCT/EP2016/072562 2016-09-22
PCT/EP2017/073858 WO2018055016A1 (en) 2016-09-22 2017-09-21 Crystalline forms

Publications (2)

Publication Number Publication Date
AU2017331930A1 AU2017331930A1 (en) 2019-03-07
AU2017331930B2 true AU2017331930B2 (en) 2021-07-15

Family

ID=59923448

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2017331930A Active AU2017331930B2 (en) 2016-09-22 2017-09-21 Crystalline forms

Country Status (27)

Country Link
US (4) US10730896B2 (enExample)
EP (2) EP3515924B1 (enExample)
JP (1) JP7097369B2 (enExample)
KR (1) KR102552795B1 (enExample)
CN (1) CN109715639B (enExample)
AU (1) AU2017331930B2 (enExample)
CA (1) CA3037794A1 (enExample)
CL (1) CL2019000728A1 (enExample)
CY (1) CY1125052T1 (enExample)
DK (1) DK3515924T3 (enExample)
EA (1) EA201990723A1 (enExample)
ES (1) ES2908572T3 (enExample)
HR (1) HRP20220234T1 (enExample)
HU (1) HUE057772T2 (enExample)
IL (1) IL265445B2 (enExample)
LT (1) LT3515924T (enExample)
MA (1) MA46266B1 (enExample)
MX (1) MX381590B (enExample)
MY (1) MY193080A (enExample)
PH (1) PH12019500567B1 (enExample)
PL (1) PL3515924T3 (enExample)
PT (1) PT3515924T (enExample)
RS (1) RS62946B1 (enExample)
SI (1) SI3515924T1 (enExample)
TW (1) TWI752086B (enExample)
UA (1) UA124073C2 (enExample)
WO (1) WO2018055016A1 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109715639B (zh) 2016-09-22 2022-04-19 爱杜西亚药品有限公司 结晶形式
SG11201908128YA (en) 2017-03-15 2019-10-30 Idorsia Pharmaceuticals Ltd Subcutaneous administration of a p2y12 receptor antagonist
TWI905227B (zh) 2020-07-15 2025-11-21 新加坡商暉致亞太私人有限公司 包含p2y12受體拮抗劑的水性醫藥組合物
CA3223733A1 (en) 2021-07-13 2023-01-19 Nicole Blumer A process for the synthesis of 4-((r)-2-{[6-((s)-3-methoxy-pyrrolidin-1-yl)-2-phenyl- pyrimidine-4-carbonyl]-amino}-3-phosphono-propionyl)-piperazine-1 -carboxylic acid butyl ester

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5373586A (en) 1976-12-09 1978-06-30 Mitsubishi Chem Ind Ltd New penicillin derivatives
CA2020437A1 (en) 1989-07-05 1991-01-06 Yoshihide Fuse Cinnamamide derivative
CA2375920A1 (en) 1999-06-14 2000-12-21 Eli Lilly And Company Compounds
US6861424B2 (en) 2001-06-06 2005-03-01 Schering Aktiengesellschaft Platelet adenosine diphosphate receptor antagonists
CN1747732A (zh) 2002-12-11 2006-03-15 舍林股份公司 作为血小板腺苷二磷酸受体拮抗剂的2-氨基羰基喹啉化合物
WO2004092189A1 (en) 2003-04-09 2004-10-28 Wyeth Derivatives of 2-(8,9-dioxo-2,6-diazabicyclo(5.2.0)non-1(7)-en-2-yl)alkyl phosphonic acid and their use as n-methyl-d-aspartate (nmda) recetor antagonists
TW200640877A (en) 2005-04-28 2006-12-01 Actelion Pharmaceuticals Ltd Pyrimidine derivatives
ES2421448T3 (es) 2005-10-21 2013-09-02 Actelion Pharmaceuticals Ltd Derivados de piperazina como agentes contra la malaria
CL2007002920A1 (es) 2006-10-13 2008-06-06 Actelion Pharmaceuticals Ltd Compuestos derivados de 2-aminocarbonilpiridina; composicion farmaceutica; y uso para el tratamiento de trastornos vasculares oclusivos.
AR063518A1 (es) 2006-10-25 2009-01-28 Actelion Pharmaceuticals Ltd Derivados 2-fenil-6-aminocarbonil-pirimidina; composicion farmaceutica; y su uso para tratar y/o prevenir enfermedades vasculares perifericas viscerales, hepaticas y renales, enfermedades cardiovasculares y enfermedades cerebrovasculares asociados con la agregacion de plaquetas, incluyendo trombosis
JP4785881B2 (ja) 2007-02-27 2011-10-05 大塚製薬株式会社 医薬
CA2684644A1 (en) 2007-04-23 2008-10-30 Sanofi-Aventis Quinoline-carboxamide derivatives as p2y12 antagonists
RU2483072C2 (ru) 2007-11-29 2013-05-27 Актелион Фармасьютиклз Лтд Производные фосфоновой кислоты и их применение в качестве антагонистов рецептора p2y12
EP2238127B1 (en) 2007-12-26 2012-08-15 Sanofi Pyrazole-carboxamide derivatives as p2y12 antagonists
EP2238128B1 (en) 2007-12-26 2012-08-22 Sanofi Heterocyclic pyrazole-carboxamides as p2y12 antagonists
AR071653A1 (es) 2008-04-11 2010-07-07 Actelion Pharmaceuticals Ltd Derivados 2-fenil-4-ciclopropil-pirimidina
AR071652A1 (es) 2008-04-11 2010-07-07 Actelion Pharmaceuticals Ltd Derivados 2- fenil-piridina substituidos
MX2011010200A (es) 2009-04-08 2011-10-14 Actelion Pharmaceuticals Ltd 6-(3-aza-biciclo[3.1.0]hex-3-il)-2fenil-pirimidinas como antagonistas del receptor de adenosina 5'-difosfato (adp).
JP5536876B2 (ja) 2009-04-22 2014-07-02 アクテリオン ファーマシューティカルズ リミテッド チアゾール誘導体及びp2y12受容体拮抗剤としてのそれらの使用
CN109715639B (zh) 2016-09-22 2022-04-19 爱杜西亚药品有限公司 结晶形式
SG11201908128YA (en) 2017-03-15 2019-10-30 Idorsia Pharmaceuticals Ltd Subcutaneous administration of a p2y12 receptor antagonist
TWI905227B (zh) 2020-07-15 2025-11-21 新加坡商暉致亞太私人有限公司 包含p2y12受體拮抗劑的水性醫藥組合物

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
BALDONI, D. et al., CLINICAL DRUG INVESTIGATION,, 2014, 34, 807 - 818 *
Brittain, H.G. in "Polymorphism in Pharmaceutical Solids", 1999, Marcel Dekker, Inc., New York, Edited by Brittain, H. G. *

Also Published As

Publication number Publication date
CL2019000728A1 (es) 2019-07-05
US10730896B2 (en) 2020-08-04
PL3515924T3 (pl) 2022-04-11
DK3515924T3 (da) 2022-03-21
NZ750772A (en) 2023-10-27
IL265445B2 (en) 2024-05-01
UA124073C2 (uk) 2021-07-14
US20200017534A1 (en) 2020-01-16
TW201813965A (zh) 2018-04-16
US12227532B2 (en) 2025-02-18
AU2017331930A1 (en) 2019-03-07
HUE057772T2 (hu) 2022-06-28
EP3515924A1 (en) 2019-07-31
MX381590B (es) 2025-03-12
EP3515924B1 (en) 2021-12-15
CY1125052T1 (el) 2024-02-16
IL265445B1 (en) 2024-01-01
JP2019529553A (ja) 2019-10-17
MA46266A (fr) 2019-07-31
US20210009614A1 (en) 2021-01-14
TWI752086B (zh) 2022-01-11
SI3515924T1 (sl) 2022-04-29
WO2018055016A1 (en) 2018-03-29
EP3981774A1 (en) 2022-04-13
US11365209B2 (en) 2022-06-21
US20250163086A1 (en) 2025-05-22
KR20190052704A (ko) 2019-05-16
PH12019500567B1 (en) 2024-01-31
US20220275011A1 (en) 2022-09-01
JP7097369B2 (ja) 2022-07-07
EA201990723A1 (ru) 2019-10-31
ES2908572T3 (es) 2022-05-03
MX2019003093A (es) 2019-07-18
PH12019500567A1 (en) 2019-11-18
RS62946B1 (sr) 2022-03-31
LT3515924T (lt) 2022-03-10
KR102552795B1 (ko) 2023-07-06
BR112019004845A2 (pt) 2019-06-04
HRP20220234T1 (hr) 2022-05-13
IL265445A (en) 2019-05-30
PT3515924T (pt) 2022-03-11
CN109715639B (zh) 2022-04-19
CA3037794A1 (en) 2018-03-29
MA46266B1 (fr) 2022-02-28
MY193080A (en) 2022-09-26
CN109715639A (zh) 2019-05-03

Similar Documents

Publication Publication Date Title
US12227532B2 (en) Crystalline forms
AU705851B2 (en) Aroyl-piperidine derivatives
JP2016510033A (ja) 強力なrock1およびrock2阻害剤としてのフェニルピラゾール誘導体
HUP0500736A2 (hu) A nitrogén (II)-oxid szintáz inhibitor hatású (S)-2-amino-4-(2-etánimidoilamino-etiltio)-vajsav-foszfátsó, eljárás előállítására és az ezt tartalmazó gyógyszerkészítmény
SK283211B6 (sk) Piperidínové zlúčeniny s analgetickým účinkom, spôsob ich prípravy, medziprodukty na ich prípravu, ich použitie, diagnostické činidlo a farmaceutické kompozície s ich obsahom
KR20130118220A (ko) 광학 활성 디아민 유도체의 염의 제조 방법
JP2021535103A (ja) グリコシダーゼ阻害剤として有用なピペラジン誘導体のコハク酸付加塩及びフマル酸付加塩
EP2485804A1 (en) Substituted phenylcarbamoyl alkylamino arene compounds and n,n'-bis-arylurea compounds
JP2015522037A (ja) ベムラフェニブコリン塩の固体形態
KR20190015305A (ko) 신장 외수질 칼륨 채널 억제제로서 약학적으로 허용 가능한 염
EP3481801B1 (en) Indoline derivatives and method for using and producing the same
HK40009744B (en) Crystalline forms
WO2019129755A1 (en) Ketal hydrogenation
NZ750772B2 (en) Crystalline forms
AU2018257332B2 (en) Heterocyclic compound
JP2011510997A (ja) 新規sEH阻害剤およびその使用
BR112019004845B1 (pt) Forma cristalina de cloridrato de éster butílico de ácido 4-((r)-2-{[6-((s) -3-metoxi-pirrolidin-1-il)-2-fenilpirimidina-4 carbonil]-amino}-3-fosfono-propionil)- piperazina-1-carboxílico, usos da mesma e de éster butílico de ácido 4-((r)-2-{[6- ((s)-3-metoxi-pirrolidin-1-il)-2- fenil-pirimidina-4-carbonil]-amino}-3- fosfonopropionil)-piperazina-1-carboxílico, ou um sal farmaceuticamente aceitável do mesmo, processos para preparação da mesma, e, composição farmacêutica
JP2025540298A (ja) Hdac阻害剤およびその使用
Zhang et al. A facile and efficient synthesis of d3‐labelled Reyataz™
EP4725944A1 (en) New method for preparing oxopyridine compound, and key intermediate and use
WO2019129750A1 (en) Processes for the racemization of dihydroimidazole ring systems
WO2019122421A1 (en) Stereoselective ketone reduction using a ketoreductase enzyme
HK1029042A (en) Ligands for sigma receptors and their therapeutical applications

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
PC Assignment registered

Owner name: VIATRIS ASIA PACIFIC PTE. LTD.

Free format text: FORMER OWNER(S): IDORSIA PHARMACEUTICALS LTD